SREBP1 as a potential biomarker predicts levothyroxine efficacy of differentiated thyroid cancer

Cuilin Li1, Xiaowei Peng2, Jing Lv3

  • 1Department of Clinical Pharmacology, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha 410008, PR China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, 110 Xiangya Road, Changsha 410078, PR China; Department of Pharmacy, The Affiliated Zhuzhou Hospital Xiangya Medical College CSU, Zhuzhou 412007, PR China.

Abstract